Founded in 1981, ZymoGenetics is a biopharmaceutical company focused on the development and commercialization of therapeutic proteins.
As a leader in recombinant technology with three decades of drug discovery and development experience, ZymoGenetics discovered and/or developed eight recombinant proteins that are currently available on the market. In addition, multiple product candidates have been out-licensed through its research efforts.
Seven are being marketed by other companies, and the eighth – RECOTHROM® Thrombin, topical (Recombinant) – is the first product that ZymoGenetics has commercialized and marketed in the US.
In October 2010, ZymoGenetics was acquired by Bristol-Myers Squibb.